Sort by
Items per page

Send to

Choose Destination

Search results

Items: 38


Bevacizumab-Based Chemotherapy Triggers Immunological Effects in Responding Multi-Treated Recurrent Ovarian Cancer Patients by Favoring the Recruitment of Effector T Cell Subsets.

Napoletano C, Ruscito I, Bellati F, Zizzari IG, Rahimi H, Gasparri ML, Antonilli M, Panici PB, Rughetti A, Nuti M.

J Clin Med. 2019 Mar 18;8(3). pii: E380. doi: 10.3390/jcm8030380.


Vascular endothelial growth factor receptor 2 (VEGFR2) correlates with long-term survival in patients with advanced high-grade serous ovarian cancer (HGSOC): a study from the Tumor Bank Ovarian Cancer (TOC) Consortium.

Guan J, Darb-Esfahani S, Richter R, Taube ET, Ruscito I, Mahner S, Woelber L, Prieske K, Concin N, Vergote I, Van Nieuwenhuysen E, Achimas-Cadariu P, Glajzer J, Woopen H, Stanske M, Kulbe H, Denkert C, Sehouli J, Braicu EI.

J Cancer Res Clin Oncol. 2019 Apr;145(4):1063-1073. doi: 10.1007/s00432-019-02877-4. Epub 2019 Feb 27.


Low endometrial beta-catenin and cadherins expression patterns are predictive for primary infertility and recurrent pregnancy loss.

Bellati F, Costanzi F, De Marco MP, Cippitelli C, Stoppacciaro A, De Angelis C, Ruscito I, Rago R, Caserta D.

Gynecol Endocrinol. 2019 Aug;35(8):727-731. doi: 10.1080/09513590.2019.1579790. Epub 2019 Feb 26.


Tumor-Derived Microvesicles Enhance Cross-Processing Ability of Clinical Grade Dendritic Cells.

Dionisi M, De Archangelis C, Battisti F, Rahimi Koshkaki H, Belleudi F, Zizzari IG, Ruscito I, Albano C, Di Filippo A, Torrisi MR, Benedetti Panici P, Napoletano C, Nuti M, Rughetti A.

Front Immunol. 2018 Nov 5;9:2481. doi: 10.3389/fimmu.2018.02481. eCollection 2018.


Characterisation of tumour microvessel density during progression of high-grade serous ovarian cancer: clinico-pathological impact (an OCTIPS Consortium study).

Ruscito I, Cacsire Castillo-Tong D, Vergote I, Ignat I, Stanske M, Vanderstichele A, Glajzer J, Kulbe H, Trillsch F, Mustea A, Kreuzinger C, Benedetti Panici P, Gourley C, Gabra H, Nuti M, Taube ET, Kessler M, Sehouli J, Darb-Esfahani S, Braicu EI.

Br J Cancer. 2018 Aug;119(3):330-338. doi: 10.1038/s41416-018-0157-z. Epub 2018 Jun 29.


The prognostic impact of cancer stem-like cell biomarker aldehyde dehydrogenase-1 (ALDH1) in ovarian cancer: A meta-analysis.

Ruscito I, Darb-Esfahani S, Kulbe H, Bellati F, Zizzari IG, Rahimi Koshkaki H, Napoletano C, Caserta D, Rughetti A, Kessler M, Sehouli J, Nuti M, Braicu EI.

Gynecol Oncol. 2018 Jul;150(1):151-157. doi: 10.1016/j.ygyno.2018.05.006. Epub 2018 May 10.


TK Inhibitor Pazopanib Primes DCs by Downregulation of the β-Catenin Pathway.

Zizzari IG, Napoletano C, Botticelli A, Caponnetto S, Calabrò F, Gelibter A, Rughetti A, Ruscito I, Rahimi H, Rossi E, Schinzari G, Marchetti P, Nuti M.

Cancer Immunol Res. 2018 Jun;6(6):711-722. doi: 10.1158/2326-6066.CIR-17-0594. Epub 2018 Apr 26.


Immunobiology of Solid Cancers: Cellular and Molecular Pathways as Potential Diagnostic and Therapeutic Targets.

Ruscito I, Braicu EI, Gasparri ML, Zizzari IG.

Biomed Res Int. 2018 Mar 1;2018:6532019. doi: 10.1155/2018/6532019. eCollection 2018. No abstract available.


Dynamics of the Intratumoral Immune Response during Progression of High-Grade Serous Ovarian Cancer.

Stanske M, Wienert S, Castillo-Tong DC, Kreuzinger C, Vergote I, Lambrechts S, Gabra H, Gourley C, Ganapathi RN, Kolaschinski I, Budczies J, Sehouli J, Ruscito I, Denkert C, Kulbe H, Schmitt W, Jöhrens K, Braicu I, Darb-Esfahani S.

Neoplasia. 2018 Mar;20(3):280-288. doi: 10.1016/j.neo.2018.01.007. Epub 2018 Feb 22.


PI3K/AKT/mTOR Pathway in Ovarian Cancer Treatment: Are We on the Right Track?

Gasparri ML, Bardhi E, Ruscito I, Papadia A, Farooqi AA, Marchetti C, Bogani G, Ceccacci I, Mueller MD, Benedetti Panici P.

Geburtshilfe Frauenheilkd. 2017 Oct;77(10):1095-1103. doi: 10.1055/s-0043-118907. Epub 2017 Oct 26.


Tumor-Derived Microvesicles Modulate Antigen Cross-Processing via Reactive Oxygen Species-Mediated Alkalinization of Phagosomal Compartment in Dendritic Cells.

Battisti F, Napoletano C, Rahimi Koshkaki H, Belleudi F, Zizzari IG, Ruscito I, Palchetti S, Bellati F, Benedetti Panici P, Torrisi MR, Caracciolo G, Altieri F, Nuti M, Rughetti A.

Front Immunol. 2017 Sep 25;8:1179. doi: 10.3389/fimmu.2017.01179. eCollection 2017.


Genetic Versus Epigenetic BRCA1 Silencing Pathways: Clinical Effects in Primary Ovarian Cancer Patients: A Study of the Tumor Bank Ovarian Cancer Consortium.

Sun T, Ruscito I, Dimitrova D, Chekerov R, Kulbe H, Baron U, Blanchard V, Panici PB, Darb-Esfahani S, Sehouli J, Olek S, Braicu EI.

Int J Gynecol Cancer. 2017 Oct;27(8):1658-1665. doi: 10.1097/IGC.0000000000001071.


The Efficacy of Fibrin Sealant Patches in Reducing the Incidence of Lymphatic Morbidity After Radical Lymphadenectomy: A Meta-Analysis.

Gasparri ML, Ruscito I, Bolla D, Benedetti Panici P, Mueller MD, Papadia A.

Int J Gynecol Cancer. 2017 Jul;27(6):1283-1292. doi: 10.1097/IGC.0000000000001051.


Exploring the clonal evolution of CD133/aldehyde-dehydrogenase-1 (ALDH1)-positive cancer stem-like cells from primary to recurrent high-grade serous ovarian cancer (HGSOC). A study of the Ovarian Cancer Therapy-Innovative Models Prolong Survival (OCTIPS) Consortium.

Ruscito I, Cacsire Castillo-Tong D, Vergote I, Ignat I, Stanske M, Vanderstichele A, Ganapathi RN, Glajzer J, Kulbe H, Trillsch F, Mustea A, Kreuzinger C, Benedetti Panici P, Gourley C, Gabra H, Kessler M, Sehouli J, Darb-Esfahani S, Braicu EI.

Eur J Cancer. 2017 Jul;79:214-225. doi: 10.1016/j.ejca.2017.04.016. Epub 2017 May 16.


Beyond circulating microRNA biomarkers: Urinary microRNAs in ovarian and breast cancer.

Gasparri ML, Casorelli A, Bardhi E, Besharat AR, Savone D, Ruscito I, Farooqi AA, Papadia A, Mueller MD, Ferretti E, Benedetti Panici P.

Tumour Biol. 2017 May;39(5):1010428317695525. doi: 10.1177/1010428317695525. Review.


Immunological and Clinical Impact of Cancer Stem Cells in Vulvar Cancer: Role of CD133/CD24/ABCG2-Expressing Cells.

Napoletano C, Bellati F, Ruscito I, Pernice M, Zizzari IG, Caponnetto S, Tomao F, Frigerio L, Liberati M, Rughetti A, Caserta D, Panici PB, Nuti M.

Anticancer Res. 2016 Oct;36(10):5109-5116.


Beyond the beyond: first case of 9 cytoreductive surgeries in a long-surviving ovarian cancer patient: case report.

Salerno L, Marchetti C, Bevilacqua E, Musella A, Riganelli L, Ruscito I, Perniola G, Muzii L, Benedetti Panici P.

Tumori. 2016 Nov 11;102(Suppl. 2). doi: 10.5301/tj.5000427.


Effects of Neoadjuvant Chemotherapy Plus Radical Surgery as Front Line Treatment Strategy in Patients Affected by FIGO Stage III Cervical Cancer.

Di Donato V, Schiavi MC, Ruscito I, Visentin VS, Palaia I, Marchetti C, Fischetti M, Monti M, Muzii L, Benedetti Panici P.

Ann Surg Oncol. 2016 Dec;23(Suppl 5):841-849. Epub 2016 Sep 27.


Sentinel Node Mapping in Cervical and Endometrial Cancer: Indocyanine Green Versus Other Conventional Dyes-A Meta-Analysis.

Ruscito I, Gasparri ML, Braicu EI, Bellati F, Raio L, Sehouli J, Mueller MD, Panici PB, Papadia A.

Ann Surg Oncol. 2016 Oct;23(11):3749-3756. doi: 10.1245/s10434-016-5236-x. Epub 2016 May 9. Review.


Triple peptide vaccination as consolidation treatment in women affected by ovarian and breast cancer: Clinical and immunological data of a phase I/II clinical trial.

Antonilli M, Rahimi H, Visconti V, Napoletano C, Ruscito I, Zizzari IG, Caponnetto S, Barchiesi G, Iadarola R, Pierelli L, Rughetti A, Bellati F, Panici PB, Nuti M.

Int J Oncol. 2016 Apr;48(4):1369-78. doi: 10.3892/ijo.2016.3386. Epub 2016 Feb 8.


Cediranib in ovarian cancer: state of the art and future perspectives.

Ruscito I, Gasparri ML, Marchetti C, De Medici C, Bracchi C, Palaia I, Imboden S, Mueller MD, Papadia A, Muzii L, Panici PB.

Tumour Biol. 2016 Mar;37(3):2833-9. doi: 10.1007/s13277-015-4781-4. Epub 2016 Jan 11. Review.


PARP inhibition: A promising therapeutic target in ovarian cancer.

Musella A, Marchetti C, Gasparri ML, Salerno L, Casorelli A, Domenici L, Imperiale L, Ruscito I, Abdul Halim T, Palaia I, Di Donato V, Pecorini F, Monti M, Muzii L, Panici PB.

Cell Mol Biol (Noisy-le-grand). 2015 Oct 30;61(6):44-61. Review.


Circulating tumor cells as trigger to hematogenous spreads and potential biomarkers to predict the prognosis in ovarian cancer.

Gasparri ML, Savone D, Besharat RA, Farooqi AA, Bellati F, Ruscito I, Panici PB, Papadia A.

Tumour Biol. 2016 Jan;37(1):71-5. doi: 10.1007/s13277-015-4299-9. Epub 2015 Oct 26. Review.


Dose-Dense Neoadjuvant Chemotherapy plus Radical Surgery in Locally Advanced Cervical Cancer: A Phase II Study.

Benedetti Panici P, Palaia I, Marchetti C, Ruscito I, Fischetti M, Musella A, Di Donato V, Perniola G, Vertechy L, Muzii L.

Oncology. 2015;89(2):103-10. doi: 10.1159/000381461. Epub 2015 Apr 29.


Advances in anti-angiogenic agents for ovarian cancer treatment: The role of trebananib (AMG 386).

Marchetti C, Gasparri ML, Ruscito I, Palaia I, Perniola G, Carrone A, Farooqi AA, Pecorini F, Muzii L, Panici PB.

Crit Rev Oncol Hematol. 2015 Jun;94(3):302-10. doi: 10.1016/j.critrevonc.2015.02.001. Epub 2015 Mar 4. Review.


BRCA1 gene promoter methylation status in high-grade serous ovarian cancer patients--a study of the tumour Bank ovarian cancer (TOC) and ovarian cancer diagnosis consortium (OVCAD).

Ruscito I, Dimitrova D, Vasconcelos I, Gellhaus K, Schwachula T, Bellati F, Zeillinger R, Benedetti-Panici P, Vergote I, Mahner S, Cacsire-Tong D, Concin N, Darb-Esfahani S, Lambrechts S, Sehouli J, Olek S, Braicu EI.

Eur J Cancer. 2014 Aug;50(12):2090-8. doi: 10.1016/j.ejca.2014.05.001. Epub 2014 Jun 2.


Dualistic classification of epithelial ovarian cancer: surgical and survival outcomes in a large retrospective series.

Panici PB, Marchetti C, Salerno L, Musella A, Vertechy L, Palaia I, Perniola G, Ruscito I, Boni T, Angioli R, Muzii L.

Ann Surg Oncol. 2014 Sep;21(9):3036-41. doi: 10.1245/s10434-014-3714-6. Epub 2014 Apr 28.


Effects of unilateral ovariectomy on female fertility outcome.

Bellati F, Ruscito I, Gasparri ML, Antonilli M, Pernice M, Vallone C, Morano G, Chirletti P, Berloco PB, Panici PB.

Arch Gynecol Obstet. 2014 Aug;290(2):349-53. doi: 10.1007/s00404-014-3194-8. Epub 2014 Mar 11.


Monoclonal antibodies therapies for ovarian cancer.

Leone Roberti Maggiore U, Bellati F, Ruscito I, Gasparri ML, Alessandri F, Venturini PL, Ferrero S.

Expert Opin Biol Ther. 2013 May;13(5):739-64. doi: 10.1517/14712598.2013.767328. Epub 2013 Feb 4. Review.


Minimal invasive approaches for large ovarian cysts: a careful choice.

Bellati F, Gasparri ML, Ruscito I, Caccetta J, Benedetti Panici P.

Arch Gynecol Obstet. 2013 Mar;287(3):615-6. doi: 10.1007/s00404-012-2560-7. Epub 2012 Sep 18. No abstract available.


Past, present and future strategies of immunotherapy in gynecological malignancies.

Bellati F, Napoletano C, Ruscito I, Visconti V, Antonilli M, Gasparri ML, Zizzari IG, Rahimi H, Palaia I, Rughetti A, Benedetti Panici P, Nuti M.

Curr Mol Med. 2013 May;13(4):648-69.


Monoclonal antibodies in gynecological cancer: a critical point of view.

Bellati F, Napoletano C, Gasparri ML, Visconti V, Zizzari IG, Ruscito I, Caccetta J, Rughetti A, Benedetti-Panici P, Nuti M.

Clin Dev Immunol. 2011;2011:890758. doi: 10.1155/2011/890758. Epub 2011 Dec 26. Review.


Current knowledge and open issues regarding bevacizumab in gynaecological neoplasms.

Bellati F, Napoletano C, Gasparri ML, Ruscito I, Marchetti C, Pignata S, Tomao F, Benedetti Panici P, Nuti M.

Crit Rev Oncol Hematol. 2012 Jul;83(1):35-46. doi: 10.1016/j.critrevonc.2011.09.006. Epub 2011 Nov 4. Review.


Immune effects of trastuzumab.

Nuti M, Bellati F, Visconti V, Napoletano C, Domenici L, Caccetta J, Zizzari IG, Ruscito I, Rahimi H, Benedetti-Panici P, Rughetti A.

J Cancer. 2011;2:317-23. Epub 2011 May 25.


Vaginal reconstruction with the Abbè-McIndoe technique: from dermal grafts to autologous in vitro cultured vaginal tissue transplant.

Panici PB, Ruscito I, Gasparri ML, Maffucci D, Marchese C, Bellati F.

Semin Reprod Med. 2011 Jan;29(1):45-54. doi: 10.1055/s-0030-1268703. Epub 2011 Feb 24. Review.


Cellular adaptive immune system plays a crucial role in trastuzumab clinical efficacy.

Bellati F, Napoletano C, Ruscito I, Liberati M, Panici PB, Nuti M.

J Clin Oncol. 2010 Jul 20;28(21):e369-70; author reply e371. doi: 10.1200/JCO.2010.28.6922. Epub 2010 May 17. No abstract available.


Complete remission of ovarian cancer induced intractable malignant ascites with intraperitoneal bevacizumab. Immunological observations and a literature review.

Bellati F, Napoletano C, Ruscito I, Pastore M, Pernice M, Antonilli M, Nuti M, Benedetti Panici P.

Invest New Drugs. 2010 Dec;28(6):887-94. doi: 10.1007/s10637-009-9351-4. Epub 2009 Nov 24. Review.


Supplemental Content

Loading ...
Support Center